Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Amilorid

Klassificering: B

Preparat: Amiloferm®, Amiloferm® mite, Amilorid Mylan, Amiloride, Midamor, Midamor®, Moduretic, Moduretic®, Moduretic® mite, Normorix, Normorix mite, Sparkal®, Sparkal® mite

ATC kod: C03DB01, C03EA01

Substanser: amilorid, amiloridhydroklorid, vattenfri, amiloridhydrokloriddihydrat

Sammanfattning

Det saknas kontrollerade studier om skillnader mellan könen avseende effekt, säkerhet och farmakokinetik för amilorid.

Additional information

Pharmacokinetics and dosing

No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of amiloride have been found.

Dosing

No studies with a clinically relevant sex analysis regarding the dosing of amiloride have been found.

Effects

No conclusive studies with a clinically relevant sex analysis regarding the effects of amiloride have been found.

Adverse effects

No studies with a clinically relevant sex analysis regarding adverse effects of amiloride have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).

Other information

A large British randomized, placebo-controlled, single-blind trial compared treatment with hydrochlorothiazide plus amiloride and atenolol in hypertensive older adults (in total 1836 men, 2560 women). Number of deaths from cancer among patients taking diuretic was higher in men than women (0.7% of men 0.3% of women on diuretics compared to 0.5% of men and 0.6% of women with placebo) [1]. These results have unclear relevance today. The cancer mortality rates in UK have fallen by 19% for women and 29% for men between 1990-2016 [2].

Försäljning på recept

Fler kvinnor än män hämtade ut tabletter innehållande amilorid (ATC-kod C03DB01) på recept i Sverige år 2018, totalt 2 913 kvinnor och 1 810 män. Det motsvarar 0,6 respektive 0,4 personer per tusen invånare. Andelen som hämtat ut läkemedel var högst i åldersgruppen 85 år och äldre hos båda könen. I genomsnitt  var tabletter innehållande amilorid 1,6 gånger vanligare hos kvinnor [3].

Uppdaterat: 2019-04-08

Litteratursökningsdatum: 2019-03-11

Referenser

  1. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results . British Medical Journal. 1992;304:405-412.
  2. Cancer Research UK. Cancer Stats: Cancer Statistics for the UK. Cancer Research UK [www]. [cited 2019-03-28]. länk
  3. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2018 [cited 2019-03-08.] länk

Författare: Linnéa Karlsson Lind

Faktagranskat av: Mia von Euler

Godkänt av: Karin Schenck-Gustafsson